Daniel Burgess - Chairman

SV Life Sciences

Mr. Burgess is Venture Partner at SV Life Sciences. Previously, he was President and Chief Executive Officer of Rempex Pharmaceuticals, an antibiotics company he co-founded in 2011 and subsequently sold to The Medicines Company in 2013. Prior to this, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, a company that advanced an inhaled antibiotic for cystic fibrosis into Phase 3 before it was acquired by Aptalis Inc. in 2011. Previously, he served as Chief Operating Officer and Chief Financial Officer of Hollis-Eden Pharmaceuticals, a public biotechnology company focused on biodefense, infectious diseases, and immune system disorders. Prior to this, Mr. Burgess spent 10 years at Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Ltd), where he held a variety of executive-level positions with responsibility for overall finance for the company. He began his career at Castle & Cooke, and Smith Barney, Harris Upham and Company. Mr. Burgess is Chairman of Atox Bio, and a Board member of Cidara Therapeutics, Arsanis, Arbutus Biopharma Corp. and Pulmocide. He received a BA degree in economics from Stanford University and an MBA degree from Harvard Business School.

Axel Bolte

HBM Partners

Axel Bolte has served as a member of our board of directors since 2007. Since February 2017, Mr. Bolte has served as director, president and chief executive officer of Inozyme Pharma Inc., a private biotechnology company. Mr. Bolte also serves as a venture partner at HBM Partners AG, a provider of investment advisory services in the life sciences industry, where he previously served as an investment advisor from March 2003 until January 2017. Mr. Bolte currently serves on the board of directors of Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) and Ophthotech Corporation (NASDAQ: OPHT) and previously served on the board of directors of PTC Therapeutics, Inc. (NASDAQ: PTCT), all of which are publicly traded biotechnology companies. Mr. Bolte received a degree in biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an M.B.A. from the University of St. Gallen, Switzerland. We believe that Mr. Bolte is qualified to serve on our board of directors because of his many years of service as one of our directors, his extensive experience as a venture capital investor in the life sciences industry and his service on the board of directors of other life sciences companies.

Carrie Bourdow

Trevena, Inc.

Ms. Bourdow has served as Senior Vice President and Chief Commercial Officer of Trevena since 2015. Previously, she was Vice President of Marketing, Reimbursement and Operations at Cubist Pharmaceuticals, Inc. Prior to joining Cubist, she spent more than 20 years at Merck & Co., Inc., where she held positions across several therapeutic areas including anti-infectives, acute heart failure and pain. Ms. Bourdow holds a B.A. degree from Hendrix College and earned her M.B.A. from Southern Illinois University.

Colin Broom

Nabriva Therapeutics, plc

Colin Broom joined Nabriva Therapeutics in August 2014. He has a bachelor of science degree in pharmacology from University College, London and a bachelor of medicine and surgery degree from St. George’s Hospital Medical School, London. He is a Member of the UK Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine. Over the past 30 years Colin has been involved in all stages of drug development and commercialization. Most recently, he served as Chief Scientific Officer at ViroPharma, Inc., (now Shire). Previous positions have included a range of leadership positions with Amgen, Hoechst Marion Roussel (now Sanofi), SmithKline Beecham and Glaxo (now GlaxoSmithKline).

Mark Corrigan, M.D.

Formerly of Zalicus, Inc.

Dr. Corrigan is former President and Chief Executive Officer of Zalicus, Inc. Previously, Dr. Corrigan was Executive Vice President of Research and Development at the specialty pharmaceutical company Sepracor Inc., and prior to this, he spent 10 years with Pharmacia & Upjohn, most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Before entering the healthcare industry, Dr. Corrigan was in academic research at the University of North Carolina at Chapel Hill School of Medicine, where he maintains a faculty appointment as Adjunct Professor in the Psychiatry Department. Dr. Corrigan served on the Board of Directors for Cubist Pharmaceuticals and of Avanir Pharmaceuticals prior to their acquisitions by Merck and Otsuka Holdings, respectively, and served as chairman of EPIRUS Biopharmaceuticals’ Board. Dr. Corrigan holds an M.D. degree from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.

George Talbot

Talbot Advisors LLC

George H. Talbot, M.D., FACP, FIDSA, an infectious diseases physician by training, began his pharmaceutical career in anti-infective drug development at Rhone-Poulenc Rorer, later Aventis.  He founded his consultancy firm, Talbot Advisors LLC, in 2000. Dr. Talbot served as EVP and CMO of Cerexa (purchased by Forest Laboratories in 2007), and worked closely with Calixa Therapeutics (acquired by Cubist Pharmaceuticals, 2009) and Durata Therapeutics (purchased by Actavis Plc, 2014). In addition to his role on Nabriva’s Supervisory Board, he chairs its Clinical Advisory Board. Dr. Talbot was a founding member of IDSA's Antimicrobial Availability Task Force ("Bad Bugs, No Drugs"), and co-Chairs the ABSSSI/CABP and HABP/VABP Project Teams at the Biomarkers Consortium of the Foundation of the National Institutes of Health.

Charles Rowland

Independent Consultant

Charles A. Rowland, Jr., CPA, MBA is a member of the board of directors of Blueprint Pharmaceuticals. Charles was most recently the CEO of Aurinia Pharmaceuticals. He was previously the VP and CFO of ViroPharma Inc., until it was acquired by Shire plc in January 2014. He has over 35 years of diversified experience in pharmaceutical operations and all areas of finance and accounting. Prior to joining ViroPharma in 2008, he was EVP and CFO, for Endo Pharmaceuticals, as well as, interim Co-CEO. Charles held positions of increasing responsibility at Biovail Corporation, Breakaway Technologies, Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb Co. He holds an MBA from Rutgers University and a BS in Accounting from Saint Joseph's University.

Stephen Webster

Spark Therapeutics

Mr. Webster is Chief Financial Officer of gene therapy company Spark Therapeutics. He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals, Inc., a biotechnology company developing specialty drugs to treat gastrointestinal infections and related diseases, until its acquisition by Cubist Pharmaceuticals. Prior to this, Mr. Webster served as Senior Vice President and Chief Financial Officer of Adolor Corporation, also acquired by Cubist. Previously, Mr. Webster served as Managing Director, Investment Banking Division, Health Care Group for Broadpoint Capital Inc. (formerly First Albany Capital). He also was co-founder and served as President and Chief Executive Officer of Neuronyx, Inc., a biopharmaceutical company. Prior to this, Mr. Webster held positions of increasing responsibility, including as Director, Investment Banking Division, Health Care Group, for PaineWebber Incorporated. Mr. Webster holds an AB degree in economics cum laude from Dartmouth College and an MBA in finance from The Wharton School of the University of Pennsylvania.